Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy?

Core Insights - Zacks Premium offers various tools to help investors make informed decisions and enhance their confidence in stock market investments [1][2] Zacks Style Scores - The Zacks Style Scores are indicators designed to assist investors in selecting stocks with the highest potential to outperform the market within a 30-day timeframe [3] - Stocks are rated from A to F based on their value, growth, and momentum characteristics, with A indicating the highest potential for outperformance [3] Value Score - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [4] Growth Score - The Growth Score evaluates a company's financial health and future prospects by analyzing projected and historical earnings, sales, and cash flow [5] Momentum Score - The Momentum Score helps investors capitalize on price trends by assessing short-term price changes and earnings estimate revisions [6] VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive indicator for stock selection [7] Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios [8] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [9] Stock Selection Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [11] - Stocks with lower ranks but high Style Scores may still be considered, provided they show potential for upside [11][12] Company Spotlight: Cencora - Cencora, based in Chesterbrook, PA, is a leading pharmaceutical services company focused on drug distribution and healthcare cost reduction [13] - Cencora holds a Zacks Rank of 2 (Buy) and a VGM Score of B, indicating strong growth potential [13] - The company is projected to achieve year-over-year earnings growth of 11.6% for the current fiscal year, with upward revisions in earnings estimates from analysts [14]